Improvement of myocardial layer injection in mice
Received date: 2017-10-30
Online published: 2017-12-30
An improved myocardial layer injection acts as an effectual mode of administration was established. Used improved syringe, Evans Blue and green fluorescent protein(GFP) labeled lentivirus were injected in to mouse myocardial layer. Evans Blue and lentivirus were found to be stored in mouse myocardial layer, and GFP could stably express in the whole heart for a long time. In conclusion, an improved myocardial layer injection may be used to cardiovascular disease (CVD) research and gene therapy research because of the good uniformity and high success rate.
WANG Hui, ZHAO Rong, ZHOU Xuezhong . Improvement of myocardial layer injection in mice[J]. Journal of Shanghai University, 2017 , 23(6) : 835 . DOI: 10.12066/j.issn.1007-2861.1969
[1] Benjamin E J, Blaha M J, Chiuve S E, et al. Heart disease and stroke statistics-2017 update: a report from the american heart association [J]. Circulation, 2017, 135(10): e634-e1003.
[2] Catucci M, Prete F, Bosticardo M, et al. Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome [J]. Gene Therapy, 2012, 19(12): 1150-1158.
[3] Tilemann L, Ishikawa K, Weber T, et al. Gene therapy for heart failure [J]. Circulation Research, 2012, 110(5): 777-793.
[4] Su C H, Wu Y J, Wang H H, et al. Nonviral gene therapy targeting cardiovascular system[J]. American Journal of Physiology Heart & Circulatory Physiology, 2012, 303(6): 629-638.
[5] Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery [J]. Annual Review of Biomedical Engineering, 2007, 9: 415-447.
[6] Bei Y, Xu T, L¨U D, et al. Exercise-induced circulating extracellular vesicles protect against cardiac ischemia-reperfusion injury [J]. Basic Research in Cardiology, 2017, 112(4): 38.
[7] Eulalio A, Mano M, dal Ferro M, et al. Functional screening identifies miRNAs inducing cardiac regeneration [J]. Nature, 2012, 492(7429): 376-381.
[8] Santiagortiz J L, Schaffer D V. Adeno-associated virus (AAV) vectors in cancer gene therapy [J]. Journal of Controlled Release, 2016, 240: 287-301.
[9] Prasad K M, Xu Y, Yang Z, et al. Robust cardiomyocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution [J]. Gene Therapy,
2011, 18(1): 43-52.
[10] Pleger S T, Shan C, Ksienzyk J, et al. Cardiac AAV9-S100A1 gene therapy rescues postischemic heart failure in a preclinical large animal model [J]. Science Translational Medicine, 2011, 3(92): 92ra64.
[11] Bey K, Ciron C, Dubreil L, et al. Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders [J]. Gene Therapy, 2017,
24(5): 325-332.
[12] Martini S V, Silva A L, Ferreira D, et al. Tyrosine mutation in AAV9 capsid improves gene transfer to the mouse Lung [J]. Cellular Physiology and Biochemistry, 2016, 39(2): 544-553.
[13] Chen B D, He C H, Chen X C, et al. Targeting transgene to the heart and liver with AAV9 by different promoters [J]. Clininal and Experimental Pharmacology and Physiology, 2015, 42(10): 1108-1117.
/
| 〈 |
|
〉 |
